Table 1.
Summary of CMA, SM, murine strain, and tumor models
| CMA/comparative SM | CMA type | Mouse strain | Tumor line | Reference |
|---|---|---|---|---|
| SPI-077/cisplatin | PEGylated liposome | Female C57Bl/6 | B16 murine melanoma | Zamboni et al. (2004) |
| S-CKD602/CKD-602 | PEGylated liposome | Female CB-17 SCID | A375 human melanoma | Zamboni et al. (2007) |
| XMT-1001/CPT-11 | Conjugated agent | Female athymic nude (nu/nu) | HT-29 human colon carcinoma | Walsh et al. (2012) |
| PRINT-docetaxel/docetaxel | Non-liposomal nanoparticle | Female CB-17 SCID | SKOV-3 human ovarian carcinoma | Chu et al. (2013) |
| CSO201/cisplatin | PEGylated liposome | Female nu/nu | KB nasopharyngeal carcinoma | Farrell (2011) |
| Folate-CSO201/cisplatin | Folate-Labeled PEGylated liposome | Female nu/nu | KB nasopharyngeal carcinoma | Farrell (2011) |
| IHL-305/CPT-11 | PEGylated liposome | BALB/cA Jcl-nu/nu | ES-2 ovarian clear cell carcinoma | Konishi et al. (2012) |
| BTM-docetaxel/docetaxel | Non-liposomal nanoparticle | Female BALB/c | 4T1 | Feng et al. (2013) |
| BTM-paclitaxel/paclitaxel | Non-liposomal nanoparticle | Female BALB/c | 4T1 | Ma et al. (2013) |
| NK012/SN-38 | Conjugated agent | Female BALB/c | HT-29 colon carcinoma | Takahashi et al. (2010) |
| SP1049C/doxorubicin | Conjugated agent | Female C57Bl/6 | s.c. 3LL-M27 | Alakhov et al. (1999) |
| ENZ-2208/SN-38 | Conjugated agent | Female BALB/c | MX-1 breast carcinoma | Sapra et al. (2008) |
| PLD/doxorubicin | PEGylated liposome | Female BALB/c | A375 | Gabizon et al. (1997) |
| Liposomal daunorubicin/daunorubicin | Conventional liposome | Female CD2F1 | P-1798 lymphosarcoma solid tumors | Forssen et al. (1992) |
| Liposomal doxorubicin/doxorubicin | Conventional liposome | Male DD/S | SC115 mammary carcinoma | Mayer et al. (1990) |
| OSI-211/lurtotecan | Conventional liposome | Female nu/nu | KB (head/neck) | Desjardins et al. (2001) |
All SM docetaxel is Taxotere®. SM paclitaxel is Taxol®. Liposomal daunorubicin is DaunoXome®. Liposomal doxorubicin is Myocet®
PLD pegylated liposomal doxorubicin, SM small molecule, CMA carrier mediated agent